Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) Profit After Tax: 2020-2025

Historic Profit After Tax for Silence Therapeutics (SLN) over the last 5 years, with Sep 2025 value amounting to -$21.0 million.

  • Silence Therapeutics' Profit After Tax rose 41.04% to -$21.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.5 million, marking a year-over-year increase of 4.36%. This contributed to the annual value of -$45.3 million for FY2024, which is 16.45% up from last year.
  • According to the latest figures from Q3 2025, Silence Therapeutics' Profit After Tax is -$21.0 million, which was up 23.38% from -$27.4 million recorded in Q2 2025.
  • Silence Therapeutics' Profit After Tax's 5-year high stood at $12.3 million during Q4 2024, with a 5-year trough of -$13.6 billion in Q1 2021.
  • Its 3-year average for Profit After Tax is -$16.0 million, with a median of -$15.4 million in 2023.
  • Its Profit After Tax has fluctuated over the past 5 years, first soared by 224.58% in 2024, then plummeted by 1,134.00% in 2025.
  • Silence Therapeutics' Profit After Tax (Quarterly) stood at -$6.4 million in 2021, then plummeted by 48.71% to -$9.6 million in 2022, then dropped by 3.03% to -$9.9 million in 2023, then surged by 224.58% to $12.3 million in 2024, then soared by 41.04% to -$21.0 million in 2025.
  • Its Profit After Tax stands at -$21.0 million for Q3 2025, versus -$27.4 million for Q2 2025 and -$28.5 million for Q1 2025.